Roche adjusts Avastin franchise defense plans as PhII successor fails a key study
Vanucizumab was supposed to be Roche’s answer to the biosimilars of Avastin that are now steadily winding their way through the clinic on a short …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
